LL37: Research, Dosing, and Where to Buy in 2026
A research-first profile for LL37 (L37), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
LL37 is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, and 3 transcript dosing protocols for LL37, each linked to its source.
- Also indexed as L37.
- 3 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is LL37?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
LL37 Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Taylor | Saturday Morning Coffee Talk 6/6/26 | 00:45:58 | Taylor reported using LL37 subcutaneous injection for a fingertip injury. | anecdotal |
| Taylor | Reader Mailbag 4 - Peptide Overdoses, GLP-1 Anhedonia & Hormone Truths | 00:58:41 | Taylor suggested an 8-week LL37 cycle for acne. | anecdotal |
| Hunter | Reader Mailbag 4 - Peptide Overdoses, GLP-1 Anhedonia & Hormone Truths | 01:04:14 | Hunter reported recommending injectable LL37 after topical ivermectin for teen acne. | anecdotal |
Where to Buy LL37 in 2026
No tracked vendor recommendations for LL37 yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about LL37. Each line links to the original source.
- "Rosacea is a chronic skin inflammatory disease with a global prevalence ranging from 1% to 20%." · Yang F et al, 2024 PubMed
Research and Studies
8 PubMed-indexed papers reference LL37. Top 8 shown.
Legal Status
LL37 is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is LL37 FDA-approved?
LL37 is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for LL37?
This page aggregates 3 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on LL37?
8 PubMed-indexed paper(s) reference LL37 in our current research feed. See the Research and Studies section above for citations.